Former Shopify exec joins Houston scale-up e-commerce software company

joining the team

Fast-growing Cart.com has named its new chief people officer. Photo courtesy of Cart.com

Houston-based e-commerce software and services company Cart.com has hired a former Shopify executive as its chief people officer.

Before joining Cart.com, Lani Doyle was chief HR officer at Strategic Solutions Group, a provider of health care software. Previously, she was vice president of HR and people operations at 6 River Systems, a provider of software and robotics for warehouses. Prior to that, Doyle was head of talent development and operations at Shopify, an e-commerce platform for businesses that posted revenue of $7.1 billion in 2023.

“Cart.com is one of the fastest-growing companies in commerce today, and I’m excited to partner with our teams to help drive growth and scalability,” Doyle says in a news release. “I am eager to contribute to shaping our culture and developing programming that supports and elevates high-performing teams, ensuring we achieve our ambitious goals.”

Omair Tariq, founder and CEO of Cart.com, describes Doyle as a “strategic leader” who will help develop the startup’s continually growing team. The company, founded in 2020 in Houston, employs more than 1,600 people.

“Her deep expertise in HR strategy and talent development will be instrumental as we accelerate our growth trajectory and foster a dynamic workplace culture,” says Frank Parker, chief operating officer of Cart.com.

In February, Cart.com made another high-level executive move by promoting Joe Barth from senior vice president of fulfillment to chief logistics officer.

Cart.com has more than 6,000 customers. The company handles more than 75 million orders per year from 14 fulfillment centers in the U.S.

Earlier this year, Tariq joined the Houston Innovators Podcast to share a bit about his company's growth and its relocation from Austin back to Houston.

"I think Austin served its purpose. It certainly allowed us to be in the limelight in all the right ways, and I'm grateful for it," Tariq says on the show. "But once we got to a point, once we closed our series C round and became a unicorn ... I think we're now at a scale where the infrastructure that Houston provides is probably something that will be more attractive and useful for us in the long term."

From Your Site Articles
Softeq has named three members to its executive team. Photos courtesy of Softeq

Houston tech company adds 3 members to its C-suite

growing team

A tech development company has expanded its executive suite with three new additions to its team.

Softeq Development Corp. has hired Craig Ceccanti as COO, Albert Esser as chief delivery officer, and Edwin Lemus as chief people officer. The new hires' roles were effective as of June 1. The Houston company, founded in 1997, creates hardware and software solutions for its clients. Softeq also runs a venture fund and studio for startups from around the world.

“With the significant growth of our engineering services business plus the addition of our Venture Studio and $40 million Venture Fund, we saw an opportunity to welcome new leaders with global experience and fresh thinking to continue evolving our business and scaling for the future,” says Christopher A. Howard, founder and CEO of Softeq, in a news release. “This is a huge investment in our team, and with the addition of these three leaders to our C-suite we will centralize our global leadership team in Houston while providing support and expertise to our team across 22 countries and clients worldwide.”

About the new executives:

  • Craig Ceccanti is a serial entrepreneur. He founded Pinot’s Palette and oversaw its franchise growth and exit before joining the founding team of sEATz — now Rivalry Technologies. The sports tech startup provides a mobile ordering software for stadiums, as well as hospital and hospitality destinations. Most recently, he founded and ran T-Minus Solutions, a custom software development company. As COO, Ceccanti will oversee the day-to-day operations of Softeq and work to improve internal and external processes.
  • With three decades of experience in tech and consulting at Daimler AG, GE, Emerson, Hilti, and Dell, Albert Esser will lead the delivery organization, which includes including solutions engineering, project management, and resource management. As chief delivery officer, he's tasked with expanding "the team’s capabilities and agility by adding to the global network of consultants," per the release, as well as leading Softeq's adoption of emerging new technologies like IoT, AI/ML, vision systems, industrial automation, robotics, cloud applications, and cyber security.
  • Edwin Lemus has 22 years of talent-related experience, and, as chief people officer, he will continue to grow the Softeq team and build a company culture for the workforce that stretches across 22 offices around the world.

Softeq Venture Studio launched over a year ago with its inaugural cohort in 2021, and the fund was launched last year. The latest cohort was announced in March.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings